Long-term stability of recombinant tissue plasminogen activator at -80 C

Article English OPEN
Sperling Matthew; Shaw George J; Meunier Jason M;

<p>Abstract</p> <p>Background</p> <p>Recombinant tissue plasminogen activator (tPA) is a thrombolytic widely used clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial infarction, and deep venous thrombosis. This has led to much int... View more
  • References (5)

    Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, et al.: Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996, 27(9):1711-1718.

    Pancioli AM, Brott TG: Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS drugs 2004, 18(14):981-988.

    Loren M, Fade-Garcia LJ, Toorado MC, Navarro JL: Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thrombosis Research 1989, 56:67-76.

    Jaffe GJ, Green GD, Abrams GH: Stability of recombinant tissue plasminogen activator. American Journal of Ophthalmology 1989, 108(1):90-91.

    Wiernikowski JT, Crowther M, Clase CM, Ingram A, Andrew M, Chan AK: Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C. Lancet 2000, 355(9222):2221-2222.

  • Related Organizations (4)
  • Metrics
Share - Bookmark